Gabapentin has been reported to be useful in the management of epilepsy, neuropathic pain and post-dural puncture headache. Seventeen obstetric cases are presented in which gabapentin was used either as a primary therapy for the management of severe headache following a diagnosed dural puncture or as an analgesic adjunct in patients with dural puncture headache unresponsive to epidural blood patch. In our patients, analgesic therapy was essential to enable care of their newborns as other management options had failed or were unavailable. In nine patients we observed an excellent result with reduction of headache severity within 24 hours. Gabapentin appears potentially beneficial in the management of patients with post-dural puncture headaches.
The National Women's Hospital in Auckland, New Zealand performs approximately 7800 deliveries per annum with an epidural analgesia rate of 60% and a caesarean section rate of approximately 30%. Our inadvertent dural puncture rate varies from 0.3 to 0.5%. Data from a trial 1 and a series of two cases 2 support the use of gabapentin in the treatment of post-dural puncture headaches (PDPH).
Although epidural blood-patch (EBP) remains the gold standard for the treatment of PDPH, it is not without risk. For this reason conservative management is used initially by our department, even though the effectiveness of hydration, caffeine and various analgesics is variable and is not supported by good evidence 3 .
For the diagnosis of PDPH, the history commonly includes either a recognised unintentional dural puncture or a documented difficult epidural insertion. The classic symptoms are a severe antero-posterior headache that is postural, relieved by lying down and worsened by sitting or standing [4] [5] [6] [7] . It may also be associated with neck stiffness, photophobia, cranial nerve signs, dizziness, nausea and tinnitus [4] [5] [6] [7] . Diagnosis of PDPH must be made early in order to rule out other more significant causes of headache in the parturient 4 . These serious conditions include meningitis, intracranial haemorrhage and cortical vein thrombosis. Any indication of intracranial pathology or systemic signs such as focal neurology, pyrexia and neutrophilia should be investigated further with the involvement of neurologists or neurosurgeons.
Our protocol includes evaluation of the patient for other causes of headache, referral as needed and immediate conservative therapy. The latter consists of oral and/or intravenous fluids, oral caffeine, and regular analgesics such as paracetamol, non-steroidal anti-inflammatory drugs and opioids as required. Although the natural progression of the headache is that resolution will usually occur in one to two weeks 5 , symptoms may be so severe that the mother is unable to mobilise and care for her baby. The early efficacy of conservative treatment has been approximately 30% over the last three years in our patients. In the event that conservative treatment fails after 24 to 48 hours, we usually offer EBP unless the headache is improving.
Some of our patients with PDPH had contraindications to or had refused EBP, so our pain team attempted to identify an effective non-invasive alternative therapy. Gabapentin is approved as an anticonvulsant, is used in the treatment of acute and chronic neuropathic pain and may be useful for patients with PDPH.
In this report we present 17 patients for whom gabapentin was used either as first line therapy or as an adjunct for intractable PDPH. In all of these patients some therapy was essential to enable them to care for their newborns, but other treatments such as EBP or intravenous patient-controlled analgesia were contraindicated, declined or had failed.
METHODS
Ethics committee approval was obtained for publication of our retrospective audit data from the Northern Regional Ethics Committee of New Zealand. All patients and staff were aware that this was off-label but potential indication for an established drug. Consent was given by each patient and this was documented in the clinical notes.
Seventeen patients diagnosed with PDPH after neuraxial anaesthesia for labour analgesia or caesarean section were treated with gabapentin between 2008 and 2010. Early administration was considered for patients who declined EBP, were unable to be offered one due to underlying sepsis or in whom there was substantial difficulty with the initial epidural insertion increasing the risk of a repeat procedure. The late introduction of gabapentin occurred in nine patients who had not benefited from an EBP. Patients who had a particularly severe early headache that was refractory to conventional analgesics were also offered gabapentin.
Risk factors for PDPH and the symptoms, diagnostic considerations and treatment outcomes were recorded. For evaluation and treatment outcomes our patients were asked to score their headache on a visual analogue scale of 0 to 10 and also asked when they felt able to resume normal activity and care for their infant. Gabapentin was initiated between two and 29 (median four) days after the onset of headache. All patients received oral gabapentin 200 mg initially, while subsequent maintenance doses ranged from 100 to 300 mg three times daily, adjusted to patient tolerance of sedation or their analgesic requirement. The median duration of treatment was eight days (range one to 30 days). Patients prescribed gabapentin were reviewed daily by the pain service while in hospital. Patients discharged on gabapentin were followed up by regular phone call from the pain service and reduced their medication dose over 10 to 14 days. A summary of patient information is in Table 1 .
We defined an excellent outcome as reduction in severity of headaches to a visual analogue scale score of two out of 10 or less, accompanied by resumption of normal activity. Nine patients (53%) had an excellent result with headache resolving in 24 to 48 hours or less; three patients showed moderate improvement, either with less reduction of the intensity of headache or a slower improvement, and gabapentin was ineffective in five patients.
DISCUSSION
The obstetric population is at particularly high risk of PDPH and all patients in this series underwent neuraxial techniques for labour analgesia or caesarean section. Some PDPH is refractory to both conservative management and EBP. Not all patients can undergo, or are willing to accept, an EBP and for several patients EBP was not a therapeutic option. Gabapentin was offered after extensive further discussion with the patient. Unlike the patients described by Moore et al 8 , our patients were expected to resume normal activity promptly postoperatively and were unwilling to accept significant sedation as a side-effect, which is why we chose to prescribe low individual doses of gabapentin 200 mg or less.
The pain of PDPH is thought to arise from traction on the meninges as a result of cerebrospinal fluid loss, vasodilatation (compensation for the decreased intracranial cerebrospinal fluid volume) and irritation of meningeal nerve roots in the upright posture. This suggests several possible mechanisms for abnormal neuronal discharges. Gabapentin was developed as a synthetic gamma amino butyric acid analogue and as an anticonvulsant, but its application as an analgesic for acute and chronic pain has become widespread. It is effective against neuropathic pain (diabetic neuropathy, post-herpetic neuralgia, trigeminal neuralgia) and as prophylaxis against cluster headaches and migraines 9, 10 . There is also limited evidence for benefit in PDPH 1,2 .
The mechanism of action of gabapentin in PDPH is probably multifactorial, principally as an analgesic with anti-hyperalgesic and anti-allodynic properties. It does not decrease the cerebrospinal fluid leak but provides analgesia and inhibits central neuronal hyperexcitablity and neuronal wind-up due to an intracerebral increase in gamma amino butyric acid 12 . The gabapentin-induced reduction of pain signalling applies to migraines as well as PDPH. The primary cellular mechanism of action of gabapentin seems to be via selective inhibition of alpha 2 delta presynaptic voltage-dependent calcium channels. This leads to reduced calcium influx and inhibits the release of excitatory neurotransmitters, such as glutamate, from the primary afferent nerve, thereby stabilising neuronal activity. At the spinal cord level, modulation of presynaptic N-methyl-D-aspartate receptors also contributes 11 .
Because of the efficacy of gabapentin reported in small clinical trials and early success reported in our patients here, the drug was included in our departmental treatment guideline for the management of PDPH. However two recent articles describing research in mice 12, 13 have questioned the safety of neonatal exposure to gabapentin. The article in Cell suggests that gabapentin inhibits excitatory synapse formation in vitro and in vivo, therefore bringing into question its safety for the developing brain. Data are limited on the effects of in-utero exposure in humans and are confounded by the effects of other anti-epileptics. As a result of these concerns, our departmental guideline has been changed to limit its use to women who are not breastfeeding. There are minimal data on the neonatal effects of gabapentin through passage in breast milk. Briggs 14 notes, "because of its low molecular weight, excretion in breast milk should be expected". In the 24 cases measured by Moore 8 , the neonatal gabapentin concentrations were 86% of maternal at delivery. The neonatal kidneys show decreased excretion of gabapentin so the drug has the potential to accumulate; but in six patients studied by Oehman 15 the plasma concentrations in the breastfed infants were only 12% of the maternal plasma levels. These investigators observed no adverse effects in the infants. Reports of gabapentin use in neonates have been for seizures and pain control (at doses of 10 mg/kg) in neurologically abnormal infants, so are not comparable with our patient group 16, 17 .
In summary, gabapentin appeared effective in the majority of patients (70%) in this series, including striking relief of headaches in two patients whose headaches were refractory to treatment with multiple EBPs. In one patient (Patient 9, Table 1 ) the headache recurred when the gabapentin dose was decreased but resolved after it was increased again. Gabapentin also appeared to be useful in the majority of cases when EBP had been refused or was contraindicated. Our findings provide support for the conduct of a large randomised trial of gabapentin in this context, although we acknowledge the difficulty of conducting randomised trials in which the primary outcome is a rare event, even though our department performs 3500 neuraxial blocks annually. Furthermore, the importance of breastfeeding for the mother and baby, juxtaposed with the concerns about potential neonatal neurotoxicity, is likely to cause reluctance to recommend gabapentin for all patients with PDPH.
